Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Jul;27(4):191-193.
doi: 10.1136/ejhpharm-2020-002329.

COvid MEdicaTion (COMET) study: protocol for a cohort study

Roos S G Sablerolles #  1 , Freija E F Hogenhuis #  2 , Melvin Lafeber  1 , Bob P A van de Loo  3 , Sander D Borgsteede  4 , Eric Boersma  5 , Jorie Versmissen  1   2 , Hugo M van der Kuy  6 ; COMET Research team
Collaborators, Affiliations
Observational Study

COvid MEdicaTion (COMET) study: protocol for a cohort study

Roos S G Sablerolles et al. Eur J Hosp Pharm. 2020 Jul.

Abstract

Various theories about drugs such as ACE inhibitors or angiotensin II receptor blockers (ARBs) in relation to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and clinical outcomes of COVID-19 are circulating in both mainstream media and medical literature. These are based on the fact that ACE2 facilitates SARS-CoV-2 cell invasion via binding of a viral spike protein to ACE2. However, the effect of ACE inhibitors, ARBs and other drugs on ACE2 is unclear and all theories are based on conflicting evidence mainly from animal studies. Therefore, clinical evidence is urgently needed. The aim of this study is to investigate the relationship between use of these drugs on clinical outcome of patients with COVID-19. Patients will be included from several hospitals in Europe. Data will be collected in a user-friendly database (Digitalis) on an external server. Analyses will be adjusted for sex, age and presence of cardiovascular disease, hypertension and diabetes. These results will enable more rational choices for randomised controlled trials for preventive and therapeutic strategies in COVID-19.

Keywords: adverse effects; clinical pharmacy; hypertension; vascular medicine; virology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Similar articles

See all similar articles

Cited by

References

    1. Kuba K, Imai Y, Rao S, et al. . A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005;11:875–9. 10.1038/nm1267 - DOI - PMC - PubMed
    1. Hoffmann M, Kleine-Weber H, Schroeder S, et al. . SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271–80. 10.1016/j.cell.2020.02.052 - DOI - PMC - PubMed
    1. Yan R, Zhang Y, Li Y, et al. . Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020;367:1444–8. 10.1126/science.abb2762 - DOI - PMC - PubMed
    1. Imai Y, Kuba K, Rao S, et al. . Angiotensin-Converting enzyme 2 protects from severe acute lung failure. Nature 2005;436:112–6. 10.1038/nature03712 - DOI - PMC - PubMed
    1. Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension 2020:HYPERTENSIONAHA12015082. 10.1161/HYPERTENSIONAHA.120.15082 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances